TIGIT and cancer: As mentioned above, Tregs are superior in suppressing T cell activation, and anti-TIGIT treatment reduces the proportion of CD4+ Tregs and inhibits the suppressive ability of Tregs [39–42], suggesting another pathway for cancer immunotherapy.